Tomaz Crochemore on Clot-Phenotyping’s Role in Prevention of Irreversible Organ Damage from Fibrinolysis Shutdown
Tomaz Crochemore, Fellow at the University of Zurich, shared on LinkedIn:
”Fibrinolysis shutdown is one of the most dangerous, and still under-recognized , phenotypes of thrombotic coagulopathy in critical care.
Seen in sepsis with organ dysfunction and in a significant subset of severely injured trauma patients, this hypofibrinolytic state locks the coagulation system in a pro-thrombotic overdrive, promoting microvascular clotting, tissue hypoperfusion, and progressive organ failure.
In trauma, patients who develop persistent fibrinolysis shutdown show a dramatically increased risk of death , with some cohorts reporting up to a five-fold rise in mortality compared with those who maintain physiologic fibrinolytic activity.
These data highlight a simple truth:
“we cannot manage what we do not measure”.
Early recognition through viscoelastic clot-phenotyping is essential to identify patients trapped in this thrombotic, hypofibrinolytic phenotype and to guide precision hemostatic interventions before irreversible organ damage occurs.”

Stay updated with Hemostasis Today.
-
Jun 4, 2026, 11:07Cristina Pecorilla: PSG6 and A New Approach to Cancer-Associated Thrombosis
-
Jun 4, 2026, 10:55Jacqui McCallum: Stroke Foundation Brings Stroke Advocacy to State Parliaments
-
Jun 4, 2026, 10:47Eugene Tang: Do Dementia-Predicting Scores Work for Stroke Patients?
-
Jun 4, 2026, 10:392026 National Stroke Awards Nominations Are Now Open – Stroke Foundation
-
Jun 4, 2026, 10:29Juliana Ferreira: Blogging Stroke on Exploring Early Markers of Post-Stroke Cognitive Decline
-
Jun 4, 2026, 10:20John Noble: My First Shadowing Experience in Hematology
-
Jun 4, 2026, 10:19Why Resilience Matters for Plasma-Derived Medicinal Products – PPTA Europe
-
Jun 4, 2026, 05:42Subramamyam Penubaku: Early Recognition and Risk-Based Management of Acute Pulmonary Embolism
-
Jun 4, 2026, 05:30Raghavendra Rao: Early Endothermal Ablation and Contemporary Management of Superficial Venous Thrombosis